Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 658 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Artery Disease, Peripheral Clear all
Completed Phase 3 Interventional Results available

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

NCT01776424
View directory record Official record
Conditions
Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Jun 27, 2026, 10:23 AM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease

NCT00180544
View directory record Official record
Conditions
Renal Artery Obstruction
Interventions
Stenting: Renal Artery
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2008 · Synced Jun 27, 2026, 10:23 AM EDT
Terminated Phase 3 Interventional

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

NCT00338585
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jun 27, 2026, 10:23 AM EDT
Recruiting No phase listed Observational

The Myelin Disorders Biorepository Project

NCT03047369
View directory record Official record
Conditions
Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Not applicable Interventional

Drug Eluting Stent for the Management of PERipheral Arterial Disease Of the SFA (DESPERADO-SFA Study)

NCT02734836
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Balloon Angioplasty, Optical Coherence Tomography
Device · Other
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Phase 2 Interventional

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

NCT03304821
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
GM-CSF, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 85 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 27, 2026, 10:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study to Determine the Optimal Technique for Measurement of Ankle Blood Pressures

NCT00819598
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
BLOOD PRESSURE MEASURMENT, BLOOD PRESSURE MEASUREMENT
Procedure
Lead sponsor
Summit Doppler Systems, Inc.
Industry
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2009 · Synced Jun 27, 2026, 10:23 AM EDT
Terminated Phase 3 Interventional Results available

The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

NCT04007055
View directory record Official record
Conditions
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease, Peripheral Arterial Occlusive Disease
Interventions
Point of care screening for HPR, Ticagrelor 90mg
Diagnostic Test · Drug
Lead sponsor
Marissa Jarosinski
Other
Eligibility
18 Years to 90 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 27, 2026, 10:23 AM EDT
Completed No phase listed Observational

TRanslesIonal Assessment of Gradients During Endovascular Therapy

NCT03163199
View directory record Official record
Conditions
Peripheral Arterial Disease, Fractional Flow Reserve, Hemodynamics
Interventions
Translesional Hemodynamic Measurement
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Phase 2 Interventional

Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure

NCT00651885
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
treprostinil dienthanolmine sustained release, Placebo
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Jun 27, 2026, 10:23 AM EDT
Active, not recruiting Not applicable Interventional

A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)

NCT03477604
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
MicroStent and Standard PTA, Standard PTA
Device
Lead sponsor
Micro Medical Solution, Inc.
Industry
Eligibility
21 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Mesa, Arizona • St. Helena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 27, 2026, 10:23 AM EDT
Recruiting Phase 4 Interventional

Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis

NCT02842424
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ramipril
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Jun 27, 2026, 10:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding the Genetic Basis of Atherosclerosis and Peripheral Arterial Disease

NCT00380185
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
1,789 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

NCT00189540
View directory record Official record
Conditions
Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
Interventions
HGF plasmid, Placebo
Genetic
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Gene Therapy in Treating Critical Leg Ischemia

NCT00696124
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
VM202 2 mg, VM202 4 mg, VM202 8 mg, VM202 16 mg
Biological
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
20 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Not applicable Interventional Results available

Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter

NCT02424383
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Diseases, Arterial Occlusive Diseases
Interventions
PTA (Lutonix® 035 DCB Catheter)
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
1,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
73
States / cities
Alexander City, Alabama • Chandler, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Jun 27, 2026, 10:23 AM EDT
Completed No phase listed Observational

RISE: A Clinical Evaluation of the StarClose™ Vascular Closure System

NCT00736086
View directory record Official record
Conditions
Peripheral Vascular Disease, Cardiovascular Disease
Interventions
Vessel Closure (StarClose™)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 85 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
11
States / cities
La Jolla, California • Atlanta, Georgia • Peoria, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Not applicable Interventional Results available

Daily Step-based Exercise Using Fitness Monitors for Peripheral Artery Disease

NCT03099369
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Daily Step-based Exercise, Symptom-based Exercise, Fitbit Fitness Monitor
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Jun 27, 2026, 10:23 AM EDT
Suspended Not applicable Interventional

FRAME, External Support for Lower Limb Autologous Grafts

NCT04003480
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Artery Disease
Interventions
FRAME
Device
Lead sponsor
Vascular Graft Solutions Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Fort Wayne, Indiana • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Phase 4 Interventional Results available

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

NCT03718429
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
Interventions
Rivaroxaban 2.5 mg Tablet
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Not applicable Interventional Results available

Study of the Penumbra Coil 400 System to Treat Aneurysm

NCT01465841
View directory record Official record
Conditions
Intracranial Aneurysms, Peripheral Aneurysms
Interventions
PC 400 coils (Penumbra )
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
Not listed
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
Newport Beach, California • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD

NCT03490968
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Supervised Exercise, Vascular Assessment
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Jun 27, 2026, 10:23 AM EDT
Recruiting Phase 4 Interventional

Vascular Trial Associated Registry Pilot

NCT07076082
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
45 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 27, 2026, 10:23 AM EDT
Completed Not applicable Interventional Results available

VISIBILITY™ Iliac Study

NCT01402700
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication
Interventions
Visi-Pro™ Balloon Expandable Stent System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jun 27, 2026, 10:23 AM EDT